Document:

EX-4.2

 Exhibit 4.2 

ALZHEON, INC. 
 AMENDED
AND RESTATED STOCKHOLDERS AGREEMENT 
 This AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “Agreement”), is made as
of May 25, 2017, by and among Alzheon, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto (together with any subsequent investors or transferees, who become parties hereto as
“Investors” pursuant to Subsections 9.9(a) or 9.12 below, the “Investors”), and those certain stockholders of the Company listed on Schedule B (together with any subsequent stockholders or transferees,
who become parties hereto as “Key Holders” pursuant to Subsection 9.9(b) or 9.12 below, the “Key Holders,” and together collectively with the Investors, the “Stockholders”). 

RECITALS 

WHEREAS, certain of the Investors (the “Existing Investors”) possess registration rights, information rights, rights
of first offer, and other rights pursuant to a Stockholders Agreement, dated as of December 30, 2014, between the Company and such Investors (the “Prior Agreement”); 

WHEREAS, the Existing Investors desire to amend and restate the Prior Agreement in its entirety and to accept the rights created
pursuant to this Agreement in lieu of the rights granted to them under the Prior Agreement; 
 WHEREAS, concurrently with the
execution of this Agreement, the Company and certain of the Investors are entering into a Series B Preferred Stock Purchase Agreement (as the same may be amended and/or restated from time to time, the “Purchase Agreement”), pursuant
to which such Investors have agreed to purchase shares of Series B Preferred Stock. 
 NOW, THEREFORE, the Company and the Existing
Investors hereby agree to amend and restate the Prior Agreement in its entirety as set forth herein, and all of the parties hereto further agree as follows: 

1. Definitions. For purposes of this Agreement: 

1.1 “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly,
controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer or director of such Person or any venture capital fund now or hereafter existing that is controlled
by one or more general partners or managing members of, or shares the same management company with, such Person. 
 1.2
“Board” means the Board of Directors of the Company. 
 1.3 “Certificate of Incorporation”
means the Company’s certificate of incorporation, as may be amended and/or restated from time to time. 

 1.4 “Common Stock” means shares of the Company’s common
stock, par value $0.001 per share. 
 1.5 “Competitor” means a Person engaged, directly or indirectly
(including through any partnership, limited liability company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in discovering, developing or commercializing therapeutics for the treatment of
Alzheimer’s disease, but shall not include any financial investment firm or collective investment vehicle that, together with its Affiliates, holds less than twenty percent (20%) of the outstanding equity of any Competitor and does not, nor do
any of its Affiliates, have a right to designate any members of the board of directors of any Competitor. 
 1.6
“Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or
liability (or any action in respect thereof) arises out of or is based upon: (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or
final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or
(iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities
Act, the Exchange Act, or any state securities law. 
 1.7 “Deemed Liquidation Event” shall have the meaning
ascribed to it in the Certificate of Incorporation. 
 1.8 “Derivative Securities” means any securities or
rights convertible into, or exercisable or exchangeable for (in each case, directly or indirectly), Common Stock, including options and warrants. 

1.9 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder. 
 1.10 “Excluded Registration” means: (i) a registration relating to the sale
of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include
substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is Common Stock issuable
upon conversion of debt securities that are also being registered. 
 1.11 “Form S-1” means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 

  
 2 

 1.12 “Form S-3”
means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by
the Company with the SEC. 
 1.13 “Founder” means Dr. Martin Tolar. 

1.14 “GAAP” means generally accepted accounting principles in the United States. 

1.15 “Holder” means any holder of Registrable Securities who is a party to this Agreement. 

1.16 “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse,
sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law,
or sister-in-law, including, adoptive relationships, of a natural person referred to herein. 

1.17 “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this
Agreement. 
 1.18 “IPO” means the Company’s first underwritten public offering of its Common Stock
under the Securities Act. 
 1.19 “New Securities” means, collectively, equity securities of the Company,
whether or not currently authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity
securities. 
 1.20 “Person” means any individual, corporation, partnership, trust, limited liability
company, association or other entity. 
 1.21 “Preferred Stock” means the Series A Preferred Stock and
Series B Preferred Stock. 
 1.22 “Registrable Securities” means (i) the Common Stock issuable or
issued upon conversion of the Preferred Stock; and (ii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to,
or in exchange for or in replacement of, the shares referenced in clause (i) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not
assigned pursuant to Subsection 9.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Subsection 2.12 of this Agreement. 

1.23 “Registrable Securities then outstanding” means the number of shares determined by adding the number of
shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities. 

  
 3 

 1.24 “Restricted Securities” means the securities of the Company
required to be notated with the legend set forth in Subsection 2.11(b) hereof. 
 1.25 “Sale of the
Company” either: (a) a transaction or series of related transactions in which a Person, or a group of related Persons, acquires from stockholders of the Company shares representing more than fifty percent (50%) of the outstanding
voting power of the Company (a “Stock Sale”); or (b) a transaction that qualifies as a Deemed Liquidation Event. 

1.26 “SEC” means the Securities and Exchange Commission. 

1.27 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.28 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.29 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder. 
 1.30 “Selling Expenses” means all underwriting discounts, selling commissions, and stock
transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Subsection
2.6. 
 1.31 “Series A Director” means the director of the Company that the holders of record of the
Series A Preferred Stock are entitled to elect, exclusively as a separate class, pursuant to the Certificate of Incorporation. 

1.32 “Series A Preferred Stock” means shares of the Company’s Series A Preferred Stock, par value $0.001
per share. 
 1.33 “Series B Preferred Stock” means shares of the Company’s Series B Preferred Stock,
par value $0.001 per share. 
 1.34 “Shares” means any securities of the Company the holders of which are
entitled to vote for members of the Board, including without limitation, all shares of Common Stock and Preferred Stock, by whatever name called, now owned or subsequently acquired by a Stockholder, however acquired, whether through stock splits,
stock dividends, reclassifications, recapitalizations, similar events or otherwise. 

  
 4 

 2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Demand Registration. 

(a) Form S-1 Demand. If at any time after the earlier of (i) five (5) years after the date
of this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of a majority of the Registrable Securities then outstanding that the
Company file a Form S-1 registration statement with respect to the Registrable Securities then outstanding having an anticipated aggregate offering price, net of Selling Expenses, of at least
$15 million, then the Company shall (x) within twenty (20) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as
practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all
Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to
the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 

(b) Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of a majority of the Registrable Securities then outstanding that the Company file a Form S-3
registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $3.0 million, then the Company shall (i) within ten
(10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is given
by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified
by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 

(c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this Subsection
2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Board it would be materially detrimental to the Company and its stockholders for such registration statement to either become
effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition, corporate reorganization, or other
similar transaction involving the Company, (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential, or (iii) render the Company unable to comply with
requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly,
for a period of not more than one hundred twenty (120) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than twice in any twelve (12) month period;
and provided further that the Company shall not register any securities for its own account or that of any other stockholder during such one hundred twenty (120) day period other than an Excluded Registration. 

  
 5 

 (d) The Company shall not be obligated to effect, or to take any action to
effect, any registration pursuant to Subsection 2.1(a): (i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty
(180) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective;
(ii) after the Company has effected one (1) registration pursuant to Subsection 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Subsection 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(b) (i)
during the period that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration, provided
that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected two registrations pursuant to Subsection 2.1(b) within the
twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this Subsection 2.1(d) until such time as the applicable registration statement
has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to
Subsection 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Subsection 2.1(d). 

2.2 Company Registration. If the Company proposes to register (including, for this purpose, a registration effected by the Company for
stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give
each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of Subsection 2.3, cause to be registered all
of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Subsection 2.2 before the effective
date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with
Subsection 2.6. 
 2.3 Underwriting Requirements. 

(a) If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their
request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the
Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such
Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the 

  
 6 

 
extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in Subsection 2.4(e)) enter into an
underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Subsection 2.3, if the underwriter(s) advise(s) the Initiating Holders in writing that marketing
factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities
that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in
such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all
other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest
one hundred (100) shares. 
 (b) In connection with any offering involving an underwriting of shares of the Company’s capital
stock pursuant to Subsection 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and
its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by
stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company
shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the
underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in
proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in accordance
with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable
Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the offering be
reduced below thirty percent (30%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and
no other stockholder’s securities are included in such offering. For purposes of the provision in this Subsection 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation,
the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of
any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and 

  
 7 

 
any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling
Holder,” as defined in this sentence. 
 (c) For purposes of Subsection 2.1, a registration shall not be counted as
“effected” if, as a result of an exercise of the underwriter’s cutback provisions in Subsection 2.3(a), fewer than one hundred percent (100%) of the total number of Registrable Securities that Holders have requested to be
included in such registration statement are actually included. 
 2.4 Obligations of the Company. Whenever required under this
Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred
twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that such one hundred twenty (120) day period shall be extended for a period of time
equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration; 

(b) prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with
such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; 
 (f) use its commercially reasonable efforts to cause all such Registrable
Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

  
 8 

 (g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to
this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

(h) promptly make available for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to
such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause
the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the
accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 
 (i) notify
each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and

 (j) after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or
supplement such registration statement or prospectus. 
 In addition, the Company shall ensure that, at all times after any registration
statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act. 
 2.5 Furnish Information. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the
Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

2.6 Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or
qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and
disbursements, not to exceed $50,000, of one (1) counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required
to pay for any expenses of any registration proceeding begun pursuant to Subsection 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which
case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the 

  
 9 

 
Holders of a majority of the Registrable Securities agree to forfeit their right to one (1) registration pursuant to Subsections 2.1(a) or 
2.1(b), as the case
may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their
request and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one (1) registration pursuant to
Subsections 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of
Registrable Securities registered on their behalf. 
 2.7 Delay of Registration. No Holder shall have any right to obtain or seek an
injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. If any Registrable Securities are included in a registration statement under this
Section 2: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each selling
Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who
controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other
expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this
Subsection 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company
be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or
other aforementioned Person expressly for use in connection with such registration. 
 (b) To the extent permitted by law, each selling
Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the
Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other
Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder
expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending
any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(b) shall not apply to

  
 10 

 
amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided
further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Subsections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling
Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 
 (c) Promptly after receipt by an
indemnified party under this Subsection 2.8 of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in
respect thereof is to be made against any indemnifying party under this Subsection 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the
extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however,
that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if
representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such
action. The failure to give notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Subsection 2.8, to
the extent that such failure materially prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party
otherwise than under this Subsection 2.8. 
 (d) To provide for just and equitable contribution to joint liability under the
Securities Act in any case in which either: (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined (by the entry of a final judgment
or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Subsection 2.8
provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Subsection 2.8, then, and in each such case, such
parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying
party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of
the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to
information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however,
that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder 

  
 11 

 
pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to
contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Subsection 2.8(d), when combined with the amounts paid
or payable by such Holder pursuant to Subsection 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 

(e) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the
obligations of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive the
termination of this Agreement. 
 2.9 Reports Under Exchange Act. With a view to making available to the Holders the benefits of SEC
Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the
Company shall: 
 (a) make and keep available adequate current public information, as those terms are understood and defined in SEC Rule
144, at all times after the effective date of the registration statement filed by the Company for the IPO; 
 (b) use commercially
reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and

 (c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent
accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the
Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3
(at any time after the Company so qualifies); and (ii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at
any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form). 

2.10 “Market Stand-off” Agreement. Each Holder hereby
agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the registration by the Company for its own behalf of shares of its Common Stock or
any other equity securities under the Securities Act on a registration statement on Form S-1 or Form S-3, and ending on the date specified by the Company and the managing underwriter (such period not to
exceed one hundred eighty (180) days in the case of the IPO, or such other period as may be requested by the Company or an underwriter 

  
 12 

 
to accommodate regulatory restrictions on (1) the publication or other distribution of research reports, and (2) analyst recommendations and opinions, including, but not limited to, the
restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to
sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common
Stock (whether such shares or any such securities are then owned by the Holder or are thereafter acquired) or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of
ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Subsection 2.10
shall apply only to the IPO and shall apply to each Investor only if each officer, director and Holder owning 5% or more of the Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common
Stock agrees to similar restrictions, shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the immediate
family of the Holder, provided that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein. The underwriters in connection with such registration are intended
third-party beneficiaries of this Subsection 2.10 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute
such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Subsection 2.10 or that are necessary to give further effect thereto. 

2.11 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the
provisions and upon the conditions specified in this Agreement. 
 (b) Each certificate, instrument, or book entry representing
(i) the Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger,
consolidation, or similar event, shall (unless otherwise permitted by the provisions of Subsection 2.12(c)) be notated with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

  
 13 

 The Holders consent to the Company making a notation in its records and giving instructions to
any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.11. 

(c) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of
this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder thereof
shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably
requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the
effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without
registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or
transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the
terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144; or (y) in any transaction in which such
Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided that each transferee agrees in writing to be subject to the terms of this Subsection 2.11. Each certificate, instrument, or book
entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Subsection 2.12(b), except that such
certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities
Act. 
 2.12 Termination of Registration Rights. The right of any Holder to request registration or inclusion of Registrable
Securities in any registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earliest to occur of: 
 (a) the
closing of a Deemed Liquidation Event; 
 (b) such time as Rule 144 or another similar exemption under the Securities Act is available for
the sale of all of such Holder’s shares without limitation during a three-month period without registration; and 
 (c) the
fifth (5th) anniversary of the IPO. 

  
 14 

 3. Information Rights. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Investor that, individually or together with such
Investor’s Affiliates, holds at least 72,993 shares of Series A Preferred Stock or 22,172 shares of Series B Preferred Stock (each as adjusted for any stock split, stock dividend, combination or other recapitalization or reclassification
effected after the date hereof), provided that the Board has not reasonably determined that such Investor is a Competitor: 
 (a) as
soon as practicable, but in any event within one hundred twenty (120) days after the end of each fiscal year of the Company (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and
(iii) a statement of stockholders’ equity as of the end of such year; and 
 (b) as soon as practicable, but in any event within
forty-five (45) days after the end of each of the first three (3) quarters of each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet as of the end of such
fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be
required in accordance with GAAP). 
 If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in
respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

Notwithstanding anything else in this Subsection 3.1 to the contrary, the Company may cease providing the information set forth in this Subsection
3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC rules applicable to
such registration statement and related offering; provided that the Company’s covenants under this Subsection 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially reasonable efforts
to cause such registration statement to become effective. 
 3.2 Inspection. The Company shall permit each Investor that, individually
or together with such Investor’s Affiliates, holds at least 729,927 shares of Series A Preferred Stock or 221,729 shares of Series B Preferred Stock (each as adjusted for any stock split, stock dividend, combination or other recapitalization or
reclassification effected after the date hereof) (provided that the Board has not reasonably determined that such Investor is a Competitor), at such Investor’s expense, upon not less than ten (10) days prior notice, to visit and
inspect the Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by such
Investor; provided, however, that the Company shall not be obligated pursuant to this Subsection 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential
information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

  
 15 

 3.3 Termination of Information Rights. The covenants set forth in Subsection
3.1 and Subsection 3.2 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of
Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, whichever event occurs first. 
 3.4
Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the
Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a
result of a breach of this Subsection 3.4 by such Investor), (b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or
disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its
attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such
Investor, provided that prior to such disclosure such prospective purchaser has agreed to be bound to provisions which are the same or substantially similar to the provisions of this Subsection 3.4 (and further provided such purchaser is not
a Competitor); (iii) to any Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs such Person that such information is confidential
and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, provided that the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize
the extent of any such required disclosure. 
 4. Rights to Future Stock Issuances. 

4.1 Right of First Offer. Subject to the terms and conditions of this Subsection 4.1 and applicable securities laws, if the
Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Investor. An Investor shall be entitled to apportion the right of first offer hereby granted to it in such proportions as it deems
appropriate, among itself and its Affiliates (provided such Affiliates are not a Competitor). 
 (a) The Company shall give notice (the
“Offer Notice”) to each Investor, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes
to offer such New Securities. 
 (b) By notification to the Company within twenty (20) days after the Offer Notice is given, each
Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Investor (including all
shares of Common Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Investor) bears to the total Common Stock of the Company then
outstanding (assuming full conversion and/or exercise, as 

  
 16 

 
applicable, of all Preferred Stock and other Derivative Securities). At the expiration of such twenty (20) day period, the Company shall promptly notify each Investor that elects to purchase
or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Investor’s failure to do likewise. During the five (5) day period commencing after the Company has given such notice, each Fully
Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Investors were entitled to subscribe but that were not
subscribed for by the Investors which is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then
held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held, by
all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Subsection 4.1(b) shall occur within the later of one hundred and twenty (120) days of the date that the Offer Notice
is given and the date of initial sale of New Securities pursuant to Subsection 4.1(c). 
 (c) If all New Securities referred to in
the Offer Notice are not elected to be purchased or acquired as provided in Subsection 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Subsection 4.1(b),
offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into
an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities
shall not be offered unless first reoffered to the Investors in accordance with this Subsection 4.1. 
 (d) The right of first offer
in this Subsection 4.1 shall not be applicable to (i) Exempted Securities (as defined in the Certificate of Incorporation); (ii) shares of Common Stock issued in the IPO; or (iii) shares of Preferred Stock issued to Additional
Investors pursuant to Section 1(e) of the Purchase Agreement. 
 (e) Notwithstanding any provision hereof to the contrary, in lieu of
complying with the provisions of this Subsection 4.1, the Company may elect to give notice to the Investors within thirty (30) days after the issuance of New Securities. Such notice shall describe the type, price, and terms of the
New Securities. Each Investor shall have twenty (20) days from the date notice is given to elect to purchase up to the number of New Securities that would, if purchased by such Investor, maintain such Investor’s percentage-ownership
position, calculated as set forth in Subsection 4.1(b) before giving effect to the issuance of such New Securities. If this provision is included in the Agreement, careful attention should be paid to the denominator used in the calculation of
the pro rata participation right. The closing of such sale shall occur within sixty (60) days of the date notice is given to the Investors. 

4.2 Termination. The covenants set forth in Subsection 4.1 shall terminate and be of no further force or effect
(i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) immediately prior to the consummation
of a Deemed Liquidation Event, whichever event occurs first. 

  
 17 

 5. Voting Provisions Regarding Board of Directors. 

5.1 Size of the Board. Each Stockholder agrees to vote, or cause to be voted, all Shares owned by such Stockholder, or over which such
Stockholder has voting control, from time to time and at all times, in whatever manner as shall be necessary to ensure that the size of the Board shall be set and remain at seven (7) directors and may be increased only with the written consent
of the Investors holding Preferred Stock representing a majority of the shares of Common Stock issuable upon conversion of the then outstanding shares of Preferred Stock. 

5.2 Board Composition. Each Stockholder agrees to vote, or cause to be voted, all Shares owned by such Stockholder, or over which such
Stockholder has voting control, from time to time and at all times, in whatever manner as shall be necessary to ensure that at each annual or special meeting of stockholders at which an election of directors is held or pursuant to any written
consent of the stockholders, the following persons shall be elected to the Board: 
 (a) One (1) person designated by ABG II-Alzheon Limited, who shall serve as the Series A Director and shall initially be David Nikodem, for so long as ABG II-Alzheon Limited and its Affiliates continue to own
beneficially at least 1,459,854 shares of Series A Preferred Stock (which number is subject to appropriate adjustment for all stock splits, dividends, combinations, recapitalizations and the like), provided, that if ABG II-Alzheon Limited no longer has the right to designate the Series A Director pursuant to the foregoing clause, then the holders of a majority of the then outstanding shares of Series A Preferred Stock shall be
entitled to nominate the Series A Director for so long as at least 1,094,891 shares of Series A Preferred Stock are issued and outstanding (which number is subject to appropriate adjustment for all stock splits, dividends, combinations,
recapitalizations and the like); 
 (b) The Company’s Chief Executive Officer, who shall initially be the Founder (the “CEO
Director”), provided that if for any reason the CEO Director shall cease to serve as the Chief Executive Officer of the Company, each of the Stockholders shall promptly vote their respective Shares (i) to remove the former Chief
Executive Officer from the Board if such person has not resigned as a member of the Board and (ii) to elect such person’s replacement as Chief Executive Officer of the Company as the new CEO Director; and 

(c) Five (5) individuals designated by the holders of a majority of the then outstanding shares of Common Stock. 

To the extent that any of clauses (a) through (c) above shall not be applicable, any member of the Board who would otherwise have been designated in
accordance with the terms thereof shall instead be voted upon by all the stockholders of the Company entitled to vote thereon in accordance with, and pursuant to, the Certificate of Incorporation. 

5.3 Failure to Designate a Board Member. In the absence of any designation from the Persons or groups with the right to designate a
director as specified above, the director previously designated by them and then serving shall be reelected if still eligible to serve as provided herein. 

  
 18 

 5.4 Removal of Board Members. Each Stockholder also agrees to vote, or cause to be voted,
all Shares owned by such Stockholder, or over which such Stockholder has voting control, from time to time and at all times, in whatever manner as shall be necessary to ensure that: 

(a) no director elected pursuant to Subsections 5.2 or 5.3 of this Agreement may be removed from office
unless (i) such removal is directed or approved by the affirmative vote of the Person, or of the holders of a majority of the shares of stock, entitled under Subsection 5.2 to designate that director; or (ii) the
Person(s) originally entitled to designate or approve such director pursuant to Subsection 5.2 is no longer so entitled to designate or approve such director; 

(b) any vacancies created by the resignation, removal or death of a director elected pursuant to Subsections 5.2 or
5.3 shall be filled pursuant to the provisions of this Section 5; and 
 (c) upon the request of any party
entitled to designate a director as provided in Subsection 5.2(a) or Subsection 5.2(c) to remove such director, such director shall be removed. 

All Stockholders agree to execute any written consents required to perform the obligations of this Agreement, and the Company agrees at the request of any
party entitled to designate directors to call a special meeting of stockholders for the purpose of electing directors. 
 5.5 No
Liability for Election of Recommended Directors. No Stockholder, nor any Affiliate of any Stockholder, shall have any liability as a result of designating a person for election as a director for any act or omission by such designated person in
his or her capacity as a director of the Company, nor shall any Stockholder have any liability as a result of voting for any such designee in accordance with the provisions of this Agreement. 

5.6 Board Matters. Unless otherwise determined by the vote of a majority of the directors then in office, the Board of Directors shall
meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the directors for all reasonable out-of-pocket travel expenses incurred
(consistent with the Company’s travel policy) in connection with attending meetings of the Board of Directors. 
 6. Vote to
Increase Authorized Common Stock. Each Stockholder agrees to vote or cause to be voted all Shares owned by such Stockholder, or over which such Stockholder has voting control, from time to time and at all times, in whatever manner as shall be
necessary to increase the number of authorized shares of Common Stock from time to time to ensure that there will be sufficient shares of Common Stock available for conversion of all of the shares of Preferred Stock outstanding at any given time.

  
 19 

 7. Drag-Along Right. 

7.1 Actions to be Taken. In the event that (i) the holders of a majority in voting power of the Preferred Stock held by the
Investors (collectively, the “Selling Investors”); (ii) the Board of Directors; and (iii) the Founder approve a Sale of the Company in writing, specifying that this Section 7 shall apply to such
transaction, then each Stockholder and the Company hereby agree: 
 (a) if such transaction requires stockholder approval, with respect to
all Shares that such Stockholder owns or over which such Stockholder otherwise exercises voting power, to vote (in person, by proxy or by action by written consent, as applicable) all Shares in favor of, and adopt, such Sale of the Company (together
with any related amendment to the Restated Certificate required in order to implement such Sale of the Company) and to vote in opposition to any and all other proposals that could reasonably be expected to delay or impair the ability of the Company
to consummate such Sale of the Company; 
 (b) if such transaction is a Stock Sale, to sell the same proportion of shares of capital stock
of the Company beneficially held by such Stockholder as is being sold by the Selling Investors to the Person to whom the Selling Investors propose to sell their Shares, and, except as permitted in Subsection 7.2 below, on the same terms and
conditions as the Selling Investors; 
 (c) to execute and deliver all related documentation and take such other action in support of the
Sale of the Company as shall reasonably be requested by the Company or the Selling Investors in order to carry out the terms and provision of this Section 7, including, without limitation, executing and delivering
instruments of conveyance and transfer, and any purchase agreement, merger agreement, indemnity agreement, escrow agreement, consent, waiver, governmental filing, share certificates duly endorsed for transfer (free and clear of impermissible liens,
claims and encumbrances), and any similar or related documents; 
 (d) not to deposit, and to cause their Affiliates not to deposit, except
as provided in this Agreement, any Shares of the Company owned by such party or Affiliate in a voting trust or subject any Shares to any arrangement or agreement with respect to the voting of such Shares, unless specifically requested to do so by
the acquirer in connection with the Sale of the Company; 
 (e) to refrain from exercising any dissenters’ rights or rights of
appraisal under applicable law at any time with respect to such Sale of the Company; 
 (f) if the consideration to be paid in exchange for
the Shares pursuant to this Section 7 includes any securities and due receipt thereof by any Stockholder would require under applicable law: (x) the registration or qualification of such securities or of any person as
a broker or dealer or agent with respect to such securities; or (y) the provision to any Stockholder of any information other than such information as a prudent issuer would generally furnish in an offering made solely to “accredited
investors” as defined in Regulation D promulgated under the Securities Act the Company may cause to be paid to any such Stockholder in lieu thereof, against surrender of the Shares which would have otherwise been sold by such Stockholder, an
amount in cash equal to the fair value (as determined in good faith by the Company) of the securities which such Stockholder would otherwise receive as of the date of the issuance of such securities in exchange for the Shares; and 

  
 20 

 (g) in the event that the Selling Investors, in connection with such Sale of the Company,
appoint a stockholder representative (the “Stockholder Representative”) with respect to matters affecting the Stockholders under the applicable definitive transaction agreements following consummation of such Sale of the Company,
(x) to consent to (i) the appointment of such Stockholder Representative, (ii) the establishment of any applicable escrow, expense or similar fund in connection with any indemnification or similar obligations, and (iii) the
payment of such Stockholder’s pro rata portion (from the applicable escrow or expense fund or otherwise) of any and all reasonable fees and expenses to such Stockholder Representative in connection with such Stockholder Representative’s
services and duties in connection with such Sale of the Company and its related service as the representative of the Stockholders, and (y) not to assert any claim or commence any suit against the Stockholder Representative or any other
Stockholder with respect to any action or inaction taken or failed to be taken by the Stockholder Representative in connection with its service as the Stockholder Representative, absent fraud or willful misconduct. 

7.2 Exceptions. Notwithstanding the foregoing, a Stockholder will not be required to comply with Subsection 7.1 above in
connection with any proposed Sale of the Company (the “Proposed Sale”), unless: 
 (a) any representations and warranties
to be made by such Stockholder in connection with the Proposed Sale are limited to representations and warranties related to authority, ownership and the ability to convey title to such Shares, including, but not limited to, representations and
warranties that (i) the Stockholder holds all right, title and interest in and to the Shares such Stockholder purports to hold, free and clear of all liens and encumbrances, (ii) the obligations of the Stockholder in connection with the
transaction have been duly authorized, if applicable, (iii) the documents to be entered into by the Stockholder have been duly executed by the Stockholder and delivered to the acquirer and are enforceable against the Stockholder in accordance
with their respective terms; and (iv) neither the execution and delivery of documents to be entered into in connection with the transaction, nor the performance of the Stockholder’s obligations thereunder, will cause a breach or violation
of the terms of any agreement, law or judgment, order or decree of any court or governmental agency; 
 (b) the Stockholder shall not be
liable for the inaccuracy of any representation or warranty made by any other Person in connection with the Proposed Sale, other than the Company (except to the extent that funds may be paid out of an escrow established to cover breach of
representations, warranties and covenants of the Company as well as breach by any stockholder of any of identical representations, warranties and covenants provided by all stockholders); 

(c) the liability for indemnification, if any, of such Stockholder in the Proposed Sale and for the inaccuracy of any representations and
warranties made by the Company or its Stockholders in connection with such Proposed Sale, is several and not joint with any other Person (except to the extent that funds may be paid out of an escrow established to cover breach of representations,
warranties and covenants of the Company as well as breach by any stockholder of 

  
 21 

 
any of identical representations, warranties and covenants provided by all stockholders), and subject to the provisions of the Certificate of Incorporation related to the allocation of the
escrow, is pro rata in proportion to, and does not exceed, the amount of consideration paid to such Stockholder in connection with such Proposed Sale; and 

(d) upon the consummation of the Proposed Sale (i) each holder of each class or series of the Company’s stock will receive the same
form of consideration for their shares of such class or series as is received by other holders in respect of their shares of such same class or series of stock, (ii) each holder of Common Stock will receive the same amount of consideration per
share of Common Stock as is received by other holders in respect of their shares of Common Stock and (iii) unless the holders of (x) a majority of the Preferred Stock elect to receive a lesser amount by written notice given to the Company
at least three (3) days prior to the effective date of any such Proposed Sale, , the aggregate consideration receivable by all holders of Preferred Stock and Common Stock shall be allocated among the holders of Preferred Stock and Common Stock
on the basis of the relative liquidation preferences to which the holders of each respective series of Preferred Stock and the holders of Common Stock are entitled in a Deemed Liquidation Event (assuming for this purpose that the Proposed Sale is a
Deemed Liquidation Event) in accordance with the Company’s Certificate of Incorporation in effect immediately prior to the Proposed Sale; provided, however, that, notwithstanding the foregoing, if the consideration
to be paid in exchange for the Key Holder Shares or Investor Shares, as applicable, pursuant to this Subsection 7.2(d) includes any securities and due receipt thereof by any Key Holder or Investor would require under applicable law
(x) the registration or qualification of such securities or of any person as a broker or dealer or agent with respect to such securities; or (y) the provision to any Key Holder or Investor of any information other than such information as
a prudent issuer would generally furnish in an offering made solely to “accredited investors” as defined in Regulation D promulgated under the Securities Act, the Company may cause to be paid to any such Key Holder or Investor in lieu
thereof, against surrender of the Key Holder Shares or Investor Shares, as applicable, which would have otherwise been sold by such Key Holder or Investor, an amount in cash equal to the fair value (as determined in good faith by the Company) of the
securities which such Key Holder or Investor would otherwise receive as of the date of the issuance of such securities in exchange for the Key Holder Shares or Investor Shares, as applicable. 

7.3 Restrictions on Sales of Control of the Company. No Stockholder shall be a party to any Stock Sale unless all holders of Preferred
Stock are allowed to participate in such transaction and the consideration received pursuant to such transaction is allocated among the parties thereto in the manner specified in the Certificate of Incorporation in effect immediately prior to the
Stock Sale (as if such transaction were a Deemed Liquidation Event), unless the holders of a majority of the Preferred Stock elect otherwise, by written notice given to the Company at least three (3) days prior to the effective date of any such
transaction or series of related transactions. 
 8. Matters Requiring Series A Director Approval. So long as the holders of Series A
Preferred Stock are entitled to elect a Series A Director, the Company shall not, either directly or indirectly by amendment, merger, consolidation or otherwise, do any of the following without the approval of the Board, which approval must
include the affirmative vote of the Series A Director: 
 (a) create or authorize the creation of or issue any additional class or series
of capital stock (excluding, for the avoidance of doubt, shares of Series A Preferred Stock) having rights, preferences or privileges senior to or on parity with Series A Preferred Stock of the Corporation; 

  
 22 

 (b) create or authorize the creation of any debt security of the Company, if the aggregate
indebtedness of the Company for borrowed money following such action would exceed $200,000, other than equipment leases or bank lines of credit entered into on an arms-length basis in the ordinary course of business; 

(c) increase or decrease the size of the Board of Directors of the Corporation; or 

(d) increase the number of shares of Common Stock authorized or reserved for issuance under any equity incentive plans of the Company. 

Notwithstanding the foregoing, the consent of the Series A Director shall not be required to authorize or reserve such number of shares of Common Stock for
issuance under the Company’s 2014 Equity Incentive Plan, as may be amended and/or restated, to equal ten percent (10%) of the Company’s then outstanding Common Stock (treating for this purpose all shares of Common Stock issuable upon
exercise of or conversion of outstanding options, warrants or convertible securities, as if exercised or converted) following the final issuance of shares of Series A Preferred Stock pursuant to that certain Series A Preferred Stock Purchase
Agreement dated on or around December 30, 2014. 
 9. Miscellaneous. 

9.1 Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder
to a transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members;
or (iii) after such transfer, holds at least 72,993 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations); provided, however, that
(x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such
transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Subsection 2.10, in substantially the form attached hereto as Exhibit
A. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder’s Immediate Family
Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that all transferees who
would not qualify individually for assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any
action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to
confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

  
 23 

 9.2 Governing Law. This Agreement shall be governed by the internal law of the State of
Delaware without regard to its conflict of laws principles that would cause the application of laws of any other jurisdiction. 
 9.3
Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile,
electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly
delivered and be valid and effective for all purposes.  
 9.4 Titles and Subtitles. The titles and subtitles used in
this Agreement are for convenience only and are not to be considered in construing or interpreting this Agreement. 
 9.5 Notices.
All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or: (i) personal delivery to the party to be notified; (ii) when
sent, if sent by electronic mail or facsimile during the recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by
registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying
next-day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth on Schedule A or Schedule B hereto (as
applicable), or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or address as subsequently modified by written notice given in
accordance with this Subsection 9.5. If notice is given to the Company, a copy shall also be sent to Latham & Watkins LLP, 27th Floor, 200 Clarendon Street, Boston, MA 02116, Attention: Peter N. Handrinos, facsimile: (617) 948-6001, email: peter.handrinos@lw.com. 
 9.6 Amendments and Waivers. Any term of this Agreement
may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company, the Founder and the holders of a
majority of the Registrable Securities then outstanding; provided that the Company may in its sole discretion waive compliance with Subsection 2.11(c) (and the Company’s failure to object promptly in writing after notification of
a proposed assignment allegedly in violation of Subsection 2.11(c) shall be deemed to be a waiver); and provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the
consent of any other party. Notwithstanding the foregoing, this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such
amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to all Investors
in the same fashion if such waiver does so by its terms, notwithstanding the 

  
 24 

 
fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction). Further, this Agreement may not be amended, and no provision hereof may be
waived, in each case, in any way which would adversely affect the rights of the Key Holders hereunder in a manner disproportionate to any adverse effect such amendment or waiver would have on the rights of the Investors hereunder, without also the
written consent of the holders of at least a majority of the Shares held by the Key Holders. The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such
amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Subsection 9.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or
exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. 

9.7 Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal
or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid,
legal, and enforceable to the maximum extent permitted by law. 
 9.8 Aggregation of Stock. All shares of Registrable Securities held
or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate.

 9.9 Additional Parties. 

(a) Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of the Company’s Series B
Preferred Stock after the date hereof, whether pursuant to the Purchase Agreement or otherwise, any purchaser of such shares of Series B Preferred Stock may become a party to this Agreement by executing and delivering an additional counterpart
signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as
such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder. 
 (b) In the
event that after the date of this Agreement, the Company enters into an agreement with any Person to issue shares of capital stock to such Person (other than to a purchaser of Preferred Stock described in Subsection 9.9(a) above), following
which such Person shall hold Shares constituting one percent (1%) or more of the Company’s then outstanding capital stock (treating for this purpose all shares of Common Stock issuable upon exercise of or conversion of outstanding options,
warrants or convertible securities, as if exercised and/or converted or exchanged), then, the Company shall cause such Person, as a condition precedent to entering into such agreement, to become a party to this Agreement by executing an Adoption
Agreement in the form attached hereto as Exhibit A, agreeing to be bound by and subject to the terms of this Agreement as a Stockholder and thereafter such person shall be deemed a Stockholder for all purposes under this Agreement. 

  
 25 

 9.10 Entire Agreement. This Agreement (including any Schedules and Exhibits hereto)
constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly
canceled. 
 9.11 Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this
Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach
or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this
Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 
 9.12 Transfers of Common Stock.
Each transferee or assignee of any shares of Common Stock subject to this Agreement shall continue to be subject to the terms hereof, and, as a condition precedent to the Company’s recognizing such transfer, each transferee or assignee shall
agree in writing to be subject to each of the terms of this Agreement by executing and delivering an Adoption Agreement substantially in the form attached hereto as Exhibit A. Upon the execution and delivery of an Adoption Agreement by any
transferee, such transferee shall be deemed to be a party hereto as if such transferee were the transferor and such transferee’s signature appeared on the signature pages of this Agreement and shall be deemed to be a Key Holder and Stockholder,
as applicable. The Company shall not permit the transfer of the shares of Common Stock subject to this Agreement on its books or issue a new certificate representing any such shares unless and until such transferee shall have complied with the terms
of this Subsection 9.12. Each certificate instrument, or book entry representing the shares of Common Stock subject to this Agreement if issued on or after the date of this Agreement shall be notated by the Company with the legend set
forth in Subsection 9.13. 
 9.13 Share Certificate Legend. Each certificate, instrument, or book entry representing any
Shares issued after the date hereof shall be notated by the Company with a legend reading substantially as follows: 
 “THE SHARES
REPRESENTED HEREBY ARE SUBJECT TO A STOCKHOLDERS AGREEMENT, AS MAY BE AMENDED FROM TIME TO TIME, (A COPY OF WHICH MAY BE OBTAINED UPON WRITTEN REQUEST FROM THE COMPANY), AND BY ACCEPTING ANY INTEREST IN SUCH SHARES THE PERSON ACCEPTING SUCH INTEREST
SHALL BE DEEMED TO AGREE TO AND SHALL BECOME BOUND BY ALL THE PROVISIONS OF THAT STOCKHOLDERS AGREEMENT, INCLUDING CERTAIN RESTRICTIONS ON TRANSFER AND OWNERSHIP SET FORTH THEREIN.” 

The Company, by its execution of this Agreement, agrees that it will cause the certificates instruments, or book entry evidencing the Shares issued after the
date hereof to be notated with the legend required by this Subsection 9.13 of this Agreement, and it shall supply, free of charge, a copy of this Agreement to any holder of such Shares upon written request from such holder to the

  
 26 

 
Company at its principal office. The parties to this Agreement do hereby agree that the failure to cause the certificates, instruments, or book entry evidencing the Shares to be notated with the
legend required by this Subsection 9.13 herein and/or the failure of the Company to supply, free of charge, a copy of this Agreement as provided hereunder shall not affect the validity or enforcement of this Agreement. 

9.14 Stock Splits, Stock Dividends, etc. In the event of any issuance of Shares of the Company’s voting securities hereafter to
any of the Stockholders (including, without limitation, in connection with any stock split, stock dividend, recapitalization, reorganization, or the like), such Shares shall become subject to this Agreement and shall be endorsed with the legend set
forth in Subsection 9.13. 
 9.15 Term. The terms and conditions of Sections 5, 6 and 7 of this Agreement
shall terminate upon the earliest to occur of (a) the consummation of the IPO (other than a registration statement relating either to the sale of securities to employees of the Company pursuant to its stock option, stock purchase or similar
plan or an SEC Rule 145 transaction); or (b) the consummation of a Sale of the Company and distribution of proceeds to or escrow for the benefit of the Stockholders in accordance with the Certificate of Incorporation, provided that the
provisions of Section 7 hereof will continue after the closing of any Sale of the Company to the extent necessary to enforce the provisions of Section 7 with respect to such Sale of the Company.

 [Remainder of Page Intentionally Left Blank] 

  
 27 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	COMPANY:
	
	ALZHEON, INC.
		
	By:	 	 /s/ Martin Tolar, M.D., Ph.D.

	Name:	 	Martin Tolar, M.D., Ph.D.
	Title:	 	Chief Executive Officer and President

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	 /s/ Sagar Patal

	(signature)
		
	Name:
	 	Sagar Patal

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: KC Venture Holdings, LLC
		
	By:	 	 /s/ Manuel Kadre

		 	(signature)
		
	Name:	 	Manuel Kadre
		
	Title:	 	Member
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Richard D.
Fain

	(signature)
		
	Name:	 	Richard D. Fain

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ William
O’Reilly

	(signature)
		
	Name:	 	William O’Reilly

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Warwick Capital Partners, LLC
		
	By:	 	 /s/ Edgar D. Jannotta, Jr.

		 	(signature)
		
	Name:	 	Edgar D. Jannotta, Jr.
		
	Title:	 	Manager
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Edgar D. Jannotta, Jr. Exempt Family Trust
		
	By:	 	 /s/ Erika Pearsall

		 	(signature)
		
	Name:	 	Erika Pearsall
		
	Title:	 	Trustee
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Patrick S.
Wilmerding

	(signature)
		
	Name:	 	Patrick S. Wilmerding

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Bruce
Pettet

	(signature)
		
	Name:	 	Bruce Pettet

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Jean-Pierre Sommadossi 1998 Irrevocable Trust
		
	By:	 	 /s/ Robert L. Murphy

		 	(signature)
		
	Name:	 	Robert L. Murphy
		
	Title:	 	Trustee
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Steven J.
Wice

	(signature)
		
	Name:	 	Steven J. Wice

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Josiah T.
Austin

	(signature)
		
	Name:	 	Josiah T. Austin

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Hilltop Investments II, LLC
		
	By:	 	 /s/ Robert R. Bennett

		 	(signature)
		
	Name:	 	Robert R. Bennett
		
	Title:	 	Manager
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: AAR Associates, L.P.
		
	By:	 	 /s/ Ralph Finerman

		 	(signature)
		
	Name:	 	Ralph Finerman
		
	Title:	 	General Partner
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: ABG II – Alzheon Limited
		
	By:	 	 /s/ Yeh Shan Ju

		 	(signature)
		
	Name:	 	Yeh Shan Ju
		
	Title:	 	Director
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Picchio International Inc.
		
	By:	 	 /s/ Marc-André Blais

		 	(signature)
		
	Name:	 	Marc-André Blais
		
	Title:	 	President
	
	If Investor is an Individual:
	
	     

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Ralph
Finerman

	(signature)
		
	Name:	 	Ralph Finerman

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Robert C.
Jamo

	(signature)
		
	Name:	 	Robert C. Jamo

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Stephen R.
Mut

	(signature)
		
	Name:	 	Stephen R. Mut

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: OWC 12/23/67 Trust FBO Erik M. W. Casperson
		
	By:	 	 /s/ Erik M. W. Casperson

		 	(signature)
		
	Name:	 	Erik M. W. Casperson
		
	Title:	 	Trustee
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Dritley Family Trust
		
	By:	 	 /s/ Jeffrey A. Dritley

		 	(signature)
		
	Name:	 	Jeffrey A. Dritley
		
	Title:	 	Trustee
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ John
Hey

	(signature)
		
	Name:	 	John Hey

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: JPM Partners, LLC
		
	By:	 	 /s/ J.P. Sommadossi

		 	(signature)
		
	Name:	 	J.P. Sommadossi
		
	Title:	 	Manager
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: F. Berdon Co LLC
		
	By:	 	 /s/ Frederick Berdon

		 	(signature)
		
	Name:	 	Frederick Berdon
		
	Title:	 	Managing Member
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Hans C.
Vitzthum

	(signature)
		
	Name:	 	Hans C. Vitzthum

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ William
Raleigh

	(signature)
		
	Name:	 	William Raleigh
	
	 Executor of the estate of Jonathan Raleigh

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Klaus
Kretschmer

	(signature)
		
	Name:	 	Klaus Kretschmer

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: JPOMA Investments Corp.
		
	By:	 	 /s/ Guy Desmarais

		 	(signature)
		
	Name:	 	Guy Desmarais
		
	Title:	 	President
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Muhit
Rahman

	(signature)
		
	Name:	 	Muhit Rahman

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Mark
Versavel

	(signature)
		
	Name:	 	Mark Versavel

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Jeremy
Yu

	(signature)
		
	Name:	 	Jeremy Yu

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Macy C.
Smith

	(signature)
		
	Name:	 	Macy C. Smith

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Gregory
Miller

	(signature)
		
	Name:	 	Gregory Miller

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: BDIF LLC
		
	By:	 	 /s/ Ralph Finerman

		 	(signature)
		
	Name:	 	Ralph Finerman
		
	Title:	 	Manager
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Kevin
Beck

	(signature)
		
	Name:	 	Kevin Beck

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Biomatrix Partners, Ltd.
		
	By:	 	 /s/ G. Houston Hall

		 	(signature)
		
	Name:	 	G. Houston Hall
		
	Title:	 	General Partner
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: BMH Investments LLC
		
	By:	 	 /s/ Brenda M. Hackney

		 	(signature)
		
	Name:	 	Brenda M. Hackney
		
	Title:	 	Sole Member
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Borgen Consolidated Holdings, LLC
		
	By:	 	 /s/ Bjorn K. Borgen

		 	(signature)
		
	Name:	 	Bjorn K. Borgen
		
	Title:	 	Manager
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Laurence
Chang

	(signature)
		
	Name:	 	Laurence Chang

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Cliffline LLC
		
	By:	 	 /s/ Helen Y. Hayes

		 	(signature)
		
	Name:	 	Helen Y. Hayes
		
	Title:	 	Member
	
	If Investor is an Individual:
	
	  

	(signature)
	
	Name:

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Peter J.
Crowley

	(signature)
		
	Name:	 	Peter J. Crowley

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Cynthia Finerman Living Trust
		
	By:	 	 /s/ Cynthia Finerman

		 	(signature)
		
	Name:	 	Cynthia Finerman
		
	Title:	 	Trustee
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: DHJ Investments, LP
		
	By:	 	 /s/ Daniel H. James

		 	(signature)
		
	Name:	 	Daniel H. James
		
	Title:	 	General Partner
	
	If Investor is an Individual:
	
	  

	(signature)
		
	 Name:
	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Edward F.
Keely

	(signature)
		
	Name:	 	Edward F. Keely

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: El Chichon Partners, LLC
		
	By:	 	 /s/ Erin Burr

		 	(signature)
		
	Name:	 	Erin Burr
		
	Title:	 	Manager
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Timothy
Hogue

	(signature)
		
	Name:	 	Timothy Hogue

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Hon Haw
Siang

	(signature)
		
	Name:	 	Hon Haw Siang

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Jack T. and Judith E. Pottle Trust
		
	By:	 	 /s/ Jack T. Pottle

		 	(signature)
		
	Name:	 	Jack T. Pottle
		
	Title:	 	Trustee
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ James
Frank

	(signature)
		
	Name:	 	James Frank

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Edgar D. Jannotta, Jr. Revocable Trust
		
	By:	 	 /s/ Edgar D. Jannotta, Jr.

		 	(signature)
		
	Name:	 	Edgar D. Jannotta, Jr.
		
	Title:	 	Trustee
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Jimmie
Dresnick

	(signature)
		
	Name:	 	Jimmie Dresnick

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Jon-Erik Borgen

	(signature)
		
	Name:	 	Jon-Erik Borgen

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Petr
Kocis

	(signature)
		
	Name:	 	Petr Kocis

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Lagom LLC
		
	By:	 	 /s/ Marika Lindholm

		 	(signature)
		
	Name:	 	Marika Lindholm
		
	Title:	 	Manager
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Evan
Cascio

	(signature)
		
	Name:	 	Evan Cascio

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Madockawando Holdings, LLC
		
	By:	 	 /s/ William B. Buchanan, Jr.

		 	(signature)
		
	Name:	 	William B. Buchanan, Jr.
		
	Title:	 	Managing Partner
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Charles J.
Magolske

	(signature)
		
	Name:	 	Charles J. Magolske

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Carl D. Meyer Separate Property Trust dated December 4, 2012
		
	By:	 	 /s/ Carl D. Meyer

		 	(signature)
		
	Name:	 	Carl D. Meyer
		
	Title:	 	Trustee
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Michael J.
Gahan

	(signature)
		
	Name:	 	Michael J. Gahan

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Montauk, LLC
		
	By:	 	 /s/ William Laverack, Jr.

		 	(signature)
		
	Name:	 	William Laverack, Jr.
		
	Title:	 	Manager
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Mossrock Capital, LLC
		
	By:	 	 /s/ Thomas Malley

		 	(signature)
		
	Name:	 	Thomas Malley
		
	Title:	 	President
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Neil
Flanzraich

	(signature)
		
	Name:	 	Neil Flanzraich

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Opaleye L.P.
		
	By:	 	 /s/ James Silverman

		 	(signature)
		
	Name:	 	James Silverman
		
	Title:	 	Founder/General Partner
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Craig M.
Overlander

	(signature)
		
	Name:	 	Craig M. Overlander

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Aidan
Power

	(signature)
		
	Name:	 	Aidan Power

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Rehoboth Hundred LLC
		
	By:	 	 /s/ Joseph Ruggiero

		 	(signature)
		
	Name:	 	Joseph Ruggiero
		
	Title:	 	Manager
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Reinfrank Living Trust dated 6/13/95
		
	By:	 	 /s/ R. Rudolph Reinfrank

		 	(signature)
		
	Name:	 	R. Rudolph Reinfrank
		
	Title:	 	Trustee
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Richard
Doyle

	(signature)
		
	Name:	 	Richard Doyle

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Richard A.
Smith

	(signature)
		
	Name:	 	Richard A. Smith

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Bryan
Ritz

	(signature)
		
	Name:	 	Bryan Ritz

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Winterset Land LLC
		
	By:	 	 /s/ Ron Sachs

		 	(signature)
		
	Name:	 	Ron Sachs
		
	Title:	 	Principal
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Philip T.
Ruegger

	(signature)
		
	Name:	 	Philip T. Ruegger

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Aptus Holdings Limited (formerly Striker Asia Opportunities Fund Corporation)
		
	By:	 	 /s/ HUEN Chung Yuen Ian

		 	(signature)
		
	Name:	 	HUEN Chung Yuen Ian
		
	Title:	 	Director
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Scott A.
Katzmann

	(signature)
		
	Name:	 	Scott A. Katzmann

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ John
Skok

	(signature)
		
	Name:	 	John Skok

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Starlight Investment Holdings Limited
		
	By:	 	 /s/ David Jenner

		 	(signature)
		
	Name:	 	David Jenner
		
	Title:	 	Director
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Stephen R. Quazzo Trust dated 11/9/95
		
	By:	 	 /s/ Stephen R. Quazzo

		 	(signature)
		
	Name:	 	Stephen R. Quazzo
		
	Title:	 	Trustee
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Thomas B.
Nelson

	(signature)
		
	Name:	 	Thomas B. Nelson

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Thomas S. Murphy,
Jr.

	(signature)
		
	Name:	 	Thomas S. Murphy, Jr.

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Trust for Descendants of Charles & Elizabeth Kontulis UAD 1/27/10
		
	By:	 	 /s/ Martha F. Morse

		 	(signature)
		
	Name:	 	Martha F. Morse
		
	Title:	 	Trustee
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Kenneth D.
Weckwar

	(signature)
		
	Name:	 	Kenneth D. Weckwar

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Eliza
Wilmerding

	(signature)
		
	Name:	 	Eliza Wilmerding

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Zaffaroni Partners LP
		
	By:	 	 /s/ Alejandro Zaffaroni

		 	(signature)
		
	Name:	 	Alejandro Zaffaroni
		
	Title:	 	General Partner
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Bradley C.
Shoup

	(signature)
		
	Name:	 	Bradley C. Shoup

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ William J.
Cassano

	(signature)
		
	Name:	 	William J. Cassano

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Seymour H. Block, D.O. Defined Benefit Plan
		
	By:	 	 /s/ Seymour H. Block, DO

		 	(signature)
		
	Name:	 	Seymour H. Block
		
	Title:	 	Trustee
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Steven S.
Marco

	(signature)
		
	Name:	 	Steven S. Marco

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Thornapple River Capital Venture Fund LLC
		
	By:	 	 /s/ Genesis Ghanga

		 	(signature)
		
	Name:	 	Genesis Ghanga
		
	Title:	 	Manager
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: EBA Capital Inc.
		
	By:	 	 /s/ Evan B. Azriliant

		 	(signature)
		
	Name:	 	Evan B. Azriliant
		
	Title:	 	President
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: The Meili Trust
		
	By:	 	 /s/ Thomas Chialastri

		 	(signature)
		
	Name:	 	Thomas Chialastri
		
	Title:	 	Trustee
	
	If Investor is an Individual:
	
	  

	(signature)
		
	Name:	 	

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Igor Puzanov,
M.D.

	(signature)
		
	Name:	 	Igor Puzanov, M.D.

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
		
	Name:	 	
		
	Title:	 	
	
	If Investor is an Individual:
	
	             /s/ Petr
Sedlacek

	(signature)
		
	Name:	 	Petr Sedlacek

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 EXHIBIT A 

ADOPTION AGREEMENT 
 This
Adoption Agreement (this “Adoption Agreement”) is executed on 14/11/2017, by the undersigned (the “Holder”) pursuant to the terms of that certain Amended and Restated Stockholders Agreement dated as of
May 25, 2017 (the “Agreement”), by and among the Alzheon, Inc., a Delaware corporation (the “Company”), and certain of its stockholders, as such Agreement may be amended or amended and restated hereafter.
Capitalized terms used but not defined in this Adoption Agreement shall have the respective meanings ascribed to such terms in the Agreement. By the execution of this Adoption Agreement, the Holder agrees as follows. 

1.1 Acknowledgement. Holder acknowledges that Holder is acquiring certain shares of the capital stock of the Company (the
“Stock”) [or options, warrants, or other rights to purchase such Stock (the “Options”)], for one of the following reasons (Check the correct box): 

 

	 	☐	As a transferee of Shares from a party in such party’s capacity as an “Investor” bound by the Agreement, and after such transfer, Holder shall be considered an “Investor” and a
“Stockholder” for all purposes of the Agreement. 

  

	 	☐	As a transferee of Shares from a party in such party’s capacity as a “Key Holder” bound by the Agreement, and after such transfer, Holder shall be considered a “Key Holder” and a
“Stockholder” for all purposes of the Agreement. 

  

	 	☐	As a new Investor in accordance with Subsection 9.9(a) of the Agreement, in which case Holder will be an “Investor” and a “Stockholder” for all purposes of the Agreement. 

 

	 	☐	In accordance with Subsection 9.9(b) of the Agreement, as a new party who is not a new Investor, in which case Holder will be a “Stockholder” for all purposes of the Agreement. 

1.2 Agreement. Holder hereby (a) agrees that the Stock [Options], and any other shares of capital stock or securities required by
the Agreement to be bound thereby, shall be bound by and subject to the terms of the Agreement and (b) adopts the Agreement with the same force and effect as if Holder were originally a party thereto. 

1.3 Notice. Any notice required or permitted by the Agreement shall be given to Holder at the address or facsimile number listed below
Holder’s signature hereto. 
  

					
	HOLDER: Petr Sedlacek	  		 	ACCEPTED AND AGREED:
			
	By: /s/ Petr
Sedlacek                                        
                    	  		 	ALZHEON, INC.
	Name and Title of Signatory	  		 	
			
	Address: XXXXX	  		 	By:
                                         
                           
			
	XXXX	  		 	Name:
			
	Facsimile Number:	  		 	Title:

 EXHIBIT A 

ADOPTION AGREEMENT 
 This
Adoption Agreement (this “Adoption Agreement”) is executed on 15 November, 2017, by the undersigned (the “Holder”) pursuant to the terms of that certain Amended and Restated Stockholders
Agreement dated as of May 25, 2017 (the “Agreement”), by and among the Alzheon, Inc., a Delaware corporation (the “Company”), and certain of its stockholders, as such Agreement may be amended or amended and
restated hereafter. Capitalized terms used but not defined in this Adoption Agreement shall have the respective meanings ascribed to such terms in the Agreement. By the execution of this Adoption Agreement, the Holder agrees as follows. 

1.1 Acknowledgement. Holder acknowledges that Holder is acquiring certain shares of the capital stock of the Company (the
“Stock”) [or options, warrants, or other rights to purchase such Stock (the “Options”)], for one of the following reasons (Check the correct box): 

 

	 	☐	As a transferee of Shares from a party in such party’s capacity as an “Investor” bound by the Agreement, and after such transfer, Holder shall be considered an “Investor” and a
“Stockholder” for all purposes of the Agreement. 

  

	 	☐	As a transferee of Shares from a party in such party’s capacity as a “Key Holder” bound by the Agreement, and after such transfer, Holder shall be considered a “Key Holder” and a
“Stockholder” for all purposes of the Agreement. 

  

	 	☐	As a new Investor in accordance with Subsection 9.9(a) of the Agreement, in which case Holder will be an “Investor” and a “Stockholder” for all purposes of the Agreement. 

 

	 	☐	In accordance with Subsection 9.9(b) of the Agreement, as a new party who is not a new Investor, in which case Holder will be a “Stockholder” for all purposes of the Agreement. 

1.2 Agreement. Holder hereby (a) agrees that the Stock [Options], and any other shares of capital stock or securities required by
the Agreement to be bound thereby, shall be bound by and subject to the terms of the Agreement and (b) adopts the Agreement with the same force and effect as if Holder were originally a party thereto. 

1.3 Notice. Any notice required or permitted by the Agreement shall be given to Holder at the address or facsimile number listed below
Holder’s signature hereto. 
  

					
	HOLDER: Karel Prazak 	  		 	ACCEPTED AND AGREED:
			
	By: /s/ Karel
Prazak                                        
        	  		 	ALZHEON, INC.
	Name and Title of Signatory	  		 	
			
	Address: XXXX	  		 	By:
                                         
                           
			
	XXXX	  		 	Name:
			
	Facsimile Number:	  		 	Title:

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
	
	Name:
	
	Title:
	
	If Investor is an Individual:
	
	 /s/ James Mellon

	(signature)
	
	Name: James Mellon

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity: Cynergy Brookline Healthcare Fund, LLC
		
	By:	 	 /s/ Richard Prati

		 	(signature)
	
	Name: Richard Prati
	
	Title: Managing Member
	
	If Investor is an Individual:
	
	  

	(signature)
	
	Name:

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
	
	Name:
	
	Title:
	
	If Investor is an Individual:
	
	 /s/ Thomas Chialastri

	(signature)
	
	Name: Thomas Chialastri

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	If Investor is an Entity:
	
	Name of Entity:
		
	By:	 	  

		 	(signature)
	
	Name:
	
	Title:
	
	If Investor is an Individual:
	
	 /s/ Tatiana Kotchoubey

	(signature)
	
	Name: Tatiana Kotchoubey

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

	
	KEY HOLDERS:
	
	 /s/ Martin Tolar, M.D., Ph.D.

	Martin Tolar, M.D., Ph.D.
	
	 /s/ John Hey, Ph.D.

	John Hey, Ph.D.
	
	 /s/ Gregory Miller

	Gregory Miller
	
	 /s/ Susan Abushakra, M.D.

	Susan Abushakra, M.D.

 
			
	
	MARTIN TOLAR 2016 IRREVOCABLE TRUST F/B/O KRISTINA TOLAROVA

 
			
		
	By:	 	  

 
			
	Name: Tomas Cvrk
	Title: Trustee
	
	MARTIN TOLAR 2016 IRREVOCABLE TRUST F/B/O LUCAS TOLAR

 
			
		
	By:	 	  

 
			
	Name: Tomas Cvrk
	Title: Trustee
	
	MARTIN TOLAR 2016 IRREVOCABLE TRUST F/B/O VERONIKA LAROVA

 
			
		
	By:	 	  

 
			
	Name: Tomas Cvrk
	Title: Trustee

 
	
	
	  
 Miroslav Tolar

	
	  

Marie Tolarova

  
 [Signature Page to
Amended and Restated Stockholders Agreement – Alzheon, Inc.] 

 SCHEDULE A 

Investors 
 ABG II-Alzheon Limited 
 XXXX 

XXXX 
 Brookline Special Situations Fund, LLC 

XXXX 
 XXXX 

Jean-Pierre Sommadossi 1998 Irrevocable Trust 
 XXXX 

XXXX 
 JellyRoll LLC 

XXXX 
 XXXX 

JPM Partners, LLC 
 XXXX 

XXXX 
 Reinfrank Living Trust, dated 6/13/95 

XXXX 
 XXXX 

Shoup Revocable Trust E. 
 XXXX 

XXXX 
 Franklin M. Berger 

XXXX 
 XXXX 

Macy Curtis Smith, Jr. 
 XXXX 

XXXX 
 Ryan Pearson 

XXXX 
 XXXX 

Robert J. Silverman 
 XXXX 

XXXX 

 Patrick S. Wilmerding 

XXXX 
 XXXX 

AAR Associates, L.P. 
 XXXX 

XXXX 
 Adam M. Scotch 

XXXX 
 XXXX 

Biomatrix Partners Ltd. 
 XXXX 

XXXX 
 Bryan Ritz 

XXXX 
 XXXX 

Claire Stilwell 
 XXXX 

XXXX 
 Cliffline LLC 

XXXX 
 XXXX 

Cynergy Healthcare Investors Emerging Bridge, LLC 
 XXXX 

XXXX 
 Cynthia Finerman Living Trust 

XXXX 
 XXXX 

David Nikodem 
 XXXX 

XXXX 
 Edward F. Keely 

XXXX 
 XXXX 

 El Chichon Partners, LLC 

XXXX 
 XXXX 

F. Berdon Co. LLC 
 XXXX 

XXXX 
 Geoffry Jay 

XXXX 
 XXXX 

Hilltop Investments II, LLC 
 XXXX 

XXXX 
 Jack T. and Judith E. Pottle Trust 

XXXX 
 XXXX 

Jennifer Duncan Inheritors Trust 
 XXXX 

XXXX 
 John G. Bradley 

XXXX 
 XXXX 

John Skok 
 XXXX 

XXXX 
 Klaus Kretschmer 

XXXX 
 XXXX 

Laurence Chang 
 XXXX 

XXXX 
 Madockawando Holdings, LLC 

XXXX 
 XXXX 

Mark Afrasiabi 
 XXXX 

XXXX 

 Max Caulkins 
 XXXX

 XXXX 
 MCT Investments, LLC 

XXXX 
 XXXX 

Mossrock Capital, LLC 
 XXXX 

XXXX 
 Neal Polan 

XXXX 
 XXXX 

OWC 12/23/67 Trust FBO Erik M.W. Casperan 
 XXXX 

XXXX 
 Ralph Finerman 

XXXX 
 XXXX 

Richard A. Smith 
 XXXX 

XXXX 
 Cynergy Brookline Healthcare Fund, LLC 

XXXX 
 XXXX 

Robert C. Jamo 
 XXXX 

XXXX 
 Robert M. DiScipio 

XXXX 
 XXXX 

Scott Cohen 
 XXXX 

XXXX 
 Steven J. Wice 

XXXX 
 XXXX 

 Timothy I. Cohen 

XXXX 
 XXXX 

Wayne Pichon 
 XXXX 

XXXX 
 Wesley Knuth 

XXXX 
 XXXX 

Winterset Lane, LLC 
 XXXX 

XXXX 
 Zachary Pashel 

XXXX 
 XXXX 

Picchio International Inc. 
 XXXX 

XXXX 
 Jpoma Investments Corporation 

XXXX 
 XXXX 

Dr. Adam Hale Brockman, Ph.D. 
 XXXX 

XXXX 
 Dr. John Anthony Hey, Ph.D. 

XXXX 
 XXXX 

Gregory Leon Miller 
 XXXX 

XXXX 
 Dr. Martin Tolar, M.D., Ph.D. 

XXXX 
 XXXX 

 Dr. Mark Versavel, M.D., Ph.D. 

XXXX 
 XXXX 

Dr. Jeremy Yongxin Yu, M.D., Ph.D. 
 XXXX 

XXXX 
 DHJ Investments, LP 

XXXX 
 XXXX 

Dritley Family Trust 
 XXXX 

XXXX 
 Edgar D. Jannotta, Jr. Exempt Family Trust 

XXXX 
 XXXX 

Edgard D. Jannotta, Jr. Revocable Trust 
 XXXX 

XXXX 
 Stephen R. Quazzo Trust dated 11/9/95 

XXXX 
 XXXX 

Hill Blalock, Jr. 
 XXXX 

XXXX 
 Austin Browning 

XXXX 
 XXXX 

Stephen DAntonio 
 XXXX 

XXXX 
 Michael J. Donaghue 

XXXX 
 XXXX 

Greg Ginsberg 
 XXXX 

XXXX 

 Thomas S. Murphy, Jr. 

XXXX 
 XXXX 

Stephen R. Mut 
 XXXX 

XXXX 
 William Newbrander 

XXXX 
 XXXX 

Bruce Pettet 
 XXXX 

XXXX 
 Muhit Rahman 

XXXX 
 XXXX 

Jonathan Raleigh 
 XXXX 

XXXX 
 Bradley Shoup 

XXXX 
 XXXX 

Cameron Smalls 
 XXXX 

XXXX 
 Gary J. Strauss 

XXXX 
 XXXX 

Hans C. Vitzthum 
 XXXX 

XXXX 
 Leon Wagner 

XXXX 
 XXXX 

 Kenneth D. and Janet Wickwar 

XXXX 
 XXXX 

Jon-Erik Borgen 
 XXXX

 XXXX 
 Josiah T. Austin 

XXXX 
 XXXX 

Kevin Beck 
 XXXX 

XXXX 
 BMH Investments LLC 

XXXX 
 XXXX 

Borgen Consolidated Holdings LLC 
 XXXX 

XXXX 
 Peter J. Crowley 

XXXX 
 XXXX 

Richard Doyle 
 XXXX 

XXXX 
 Jimmie Dresnick 

XXXX 
 XXXX 

Neil Flanzraich 
 XXXX 

XXXX 
 James Frank 

XXXX 
 XXXX 

Michael J. Gahan 
 XXXX 

XXXX 

 Timothy Hogue 
 XXXX

 XXXX 
 Haw Siang Hon 

XXXX 
 XXXX 

Scott A. Katzmann 
 XXXX 

XXXX 
 Petr Kocis 

XXXX 
 XXXX 

Trust for Descendants of Charles & Elizabeth Kontulis UAD 1/27/10 

XXXX 
 XXXX 

Lagom LLC 
 XXXX 

XXXX 
 Carl D. Meyer Separate Property Trust dated
December 4, 2012 
 XXXX 
 XXXX 

Montauk, LLC 
 XXXX 

XXXX 
 Charles Magolske 

XXXX 
 XXXX 

Thomas B. Nelson 
 XXXX 

XXXX 
 Opaleye L.P. 

XXXX 
 XXXX 

 Craig M. Overlander 

XXXX 
 XXXX 

Sagar Patel 
 XXXX 

XXXX 
 Aidan Power 

XXXX 
 XXXX 

Rehoboth Hundred LLC 
 XXXX 

XXXX 
 Philip T. Ruegger 

XXXX 
 XXXX 

Starlight Investment Holdings Limited 
 XXXX 

XXXX 
 Eliza Wilmerding 

XXXX 
 XXXX 

Zaffaroni Partners LP 
 XXXX 

XXXX 
 BDIF LLC 

XXXX 
 XXXX 

Evan Cascio 
 XXXX 

XXXX 
 Warwick Capital Partners, LLC 

XXXX 
 XXXX 

William O’Reilly 
 XXXX 

XXXX 

 Richard D. Fain 

XXXX 
 XXXX 

William Cassano 
 XXXX 

XXXX 
 KC Venture Holdings, LLC 

XXXX 
 XXXX 

Kenneth Wickwar 
 XXXX 

XXXX 
 Aptus Holdings Limited 

cXXXX 
 XXXX 

Steven Marco 
 XXXX 

XXXX 
 EBA Capital Inc. 

XXXX 
 XXXX 

Thornapple River Capital Venture Fund LLC 
 XXXX 

XXXX 
 The Meili Trust 

XXXX 
 XXXX 

Igor Puzanov, M.D., M.S.C.I., F.A.C.P. 
 XXXX 

XXXX 
 Petr Sedlacek 

XXXX 
 XXXX 

 Karel Prazak 
 XXXX

 XXXX 
 James Mellon 

XXXX 
 XXXX 

Thomas Chialastri 
 XXXX 

XXXX 

 SCHEDULE B 

Key Holders 
 Martin Tolar 

XXXX 
 XXXX 

MARTIN TOLAR 2016 IRREVOCABLE TRUST F/B/O KRISTINA TOLAROVA 

XXXX 
 XXXX 

MARTIN TOLAR 2016 IRREVOCABLE TRUST F/B/O LUCAS TOLAR 
 XXXX 

XXXX 
 MARTIN TOLAR 2016 IRREVOCABLE TRUST F/B/O VERONIKA LAROVA

 XXXX 
 XXXX 

Miroslav Tolar 
 XXXX 

XXXX 
 Marie Tolarova 

XXXX 
 XXXX 

John Hey 
 XXXX 

XXXX 
 Gregory Miller 

XXXX 
 XXXX 

Susan Abushakra, M.D. 
 XXXX 

XXXX 

 EXHIBIT A 

ADOPTION AGREEMENT 
 This
Adoption Agreement (this “Adoption Agreement”) is executed on             , 20    , by the undersigned (the “Holder”) pursuant to the
terms of that certain Amended and Restated Stockholders Agreement dated as of May 25, 2017 (the “Agreement”), by and among the Alzheon, Inc., a Delaware corporation (the “Company”), and certain of its
stockholders, as such Agreement may be amended or amended and restated hereafter. Capitalized terms used but not defined in this Adoption Agreement shall have the respective meanings ascribed to such terms in the Agreement. By the execution of this
Adoption Agreement, the Holder agrees as follows. 
 1.1 Acknowledgement. Holder acknowledges that Holder is acquiring certain shares
of the capital stock of the Company (the “Stock”) [or options, warrants, or other rights to purchase such Stock (the “Options”)], for one of the following reasons (Check the correct box): 

 

	 	☐	As a transferee of Shares from a party in such party’s capacity as an “Investor” bound by the Agreement, and after such transfer, Holder shall be considered an “Investor” and a
“Stockholder” for all purposes of the Agreement. 

  

	 	☐	As a transferee of Shares from a party in such party’s capacity as a “Key Holder” bound by the Agreement, and after such transfer, Holder shall be considered a “Key Holder” and a
“Stockholder” for all purposes of the Agreement. 

  

	 	☐	As a new Investor in accordance with Subsection 9.9(a) of the Agreement, in which case Holder will be an “Investor” and a “Stockholder” for all purposes of the Agreement. 

 

	 	☐	In accordance with Subsection 9.9(b) of the Agreement, as a new party who is not a new Investor, in which case Holder will be a “Stockholder” for all purposes of the Agreement. 

1.2 Agreement. Holder hereby (a) agrees that the Stock [Options], and any other shares of capital stock or securities required by
the Agreement to be bound thereby, shall be bound by and subject to the terms of the Agreement and (b) adopts the Agreement with the same force and effect as if Holder were originally a party thereto. 

1.3 Notice. Any notice required or permitted by the Agreement shall be given to Holder at the address or facsimile number listed below
Holder’s signature hereto. 
  

									
	HOLDER:	 		 	ACCEPTED AND AGREED:
				
	By:	 	  
	 		 	ALZHEON, INC.
	Name and Title of Signatory	 		 		 	
				
	Address:	 		 	By:	 	  

				
		 		 	            	 	Name:
			
	Facsimile Number:	 		 	Title:EX-4.3

 Exhibit 4.3 

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS AND HAVE BEEN ACQUIRED FOR
INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT OR QUALIFICATION RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM
SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION OR QUALIFICATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. 

Date of
Issuance:                     

ALZHEON, INC. 
 WARRANT
TO PURCHASE SHARES OF COMMON STOCK 
 THIS CERTIFIES THAT, for value
received,                    (the “Holder”) is entitled to purchase from Alzheon, Inc., a Delaware corporation (the
“Company”), subject to the terms and conditions of this Warrant, at any time prior to the Expiration Date (as defined below), at an exercise price per Warrant Share (as defined below) of
$        (the “Exercise Price”),            shares of the Common Stock, par value $0.001, of the Company (“Common
Stock”). The shares of Common Stock purchasable upon exercise of this Warrant are hereinafter referred to as the “Warrant Shares”. The Warrant Shares and the Exercise Price are subject to further adjustment as set forth in
Section 2. 
 1. Exercise of Warrant. 

1.1 Term. Subject to Section 1.5, below, this Warrant shall terminate and no longer be exercisable on the
earliest to occur of (i) the voluntary or involuntary liquidation, dissolution or winding up of the Company, (ii) the occurrence of a Deemed Liquidation Event (as defined in the Company’s Amended and Restated Certificate of
Incorporation, filed with the Delaware Secretary of State on December 24, 2014, as may be amended and/or restated from time to time (the “Restated Certificate”), or (iii) 5:00 p.m., Eastern time,
on                    . For purposes of this Warrant, (a) “Expiration Date” means the date upon which this Warrant expires in
accordance with the terms of this Section 1.1 and (b) “Person” means an individual, firm, corporation, partnership, association, limited liability company, trust or any other entity. 

1.2 Method. This Warrant may be exercised by the Holder, in whole or in part, by: 

(a) the surrender of this Warrant (with the Notice of Exercise form attached hereto as Attachment A and the Investment Representation
Statement attached hereto as Attachment B duly executed) at the principal office of the Company; and 
 (b) the payment to the
Company, by check payable to the Company, by wire transfer to a bank account designated by the Company or by cancellation of indebtedness of the Company, of an amount equal to the Exercise Price per share multiplied by the number of Warrant Shares
then being purchased. 
 1.3 Net Exercise. In lieu of Section 1.2 hereof, the Holder may elect to convert
this Warrant or any portion thereof (the “Conversion Right”), by surrender of this Warrant at the principal office of the Company together with notice of the Holder’s intention to exercise the Conversion Right, into that number
of Warrant Shares computed using the following formula: 
 X = Y(A-B) 

A 

	 	Where:	

  

	 	X =	The number of Warrant Shares to be issued to the Holder upon exercise of the Conversion Right. 

  

	 	Y =	The number of Warrant Shares for which this Warrant is being exercised. 

  

	 	A =	The Fair Market Value (as defined below) of one Warrant Share at the time the Conversion Right is exercised. 

  

	 	B =	Exercise Price (as adjusted to the date of such calculation). 

 For purposes of
Section 1.3, “Fair Market Value” shall mean: 
 (a) If the Warrant is exercised in connection
with and contingent upon an initial public offering, and if the Company’s registration statement relating to such initial public offering has been declared effective by the Securities and Exchange Commission, then the initial “Price to
Public” specified in the final prospectus with respect to such offering. 
 (b) If the Warrant is exercised in connection with and
contingent upon a Deemed Liquidation Event, then the value ascribed to the Common Stock in such Deemed Liquidation Event, as applicable. 

(c) If the Warrant is exercised following the Company’s initial public offering, the average of the closing price of the Common Stock
quoted in the over-the-counter market in which the Common Stock is traded or the closing price quoted on any exchange or electronic securities market on which the Common
Stock is listed, whichever is applicable, for the thirty (30) trading days prior to the date of determination of the Fair Market Value (or such shorter period of time during which such Common Stock was traded over-the-counter or on such exchange). 
 (d) If none of the immediately preceding clauses (a),
(b) or (c) is applicable, then the fair market value as determined in good faith by the Board of Directors of the Company. 
 1.4
Delivery; Certificate. Upon receipt by the Company of this Warrant and a Notice of Exercise, together with, if applicable, the aggregate Exercise Price, at its principal office, or by the stock transfer agent or warrant agent of the Company
at its office, the Holder shall be deemed to be the holder of record of the Warrant Shares, notwithstanding that the stock transfer books of the Company shall then be closed or that certificates representing such Warrant Shares shall not then be
actually delivered to the Holder. The Company shall, as soon as practicable after the exercise of this Warrant in accordance with the terms hereof, direct its stock transfer agent to prepare a certificate for the applicable Warrant Shares purchased
in the name of the Holder. If this Warrant should be exercised in part only, the Company shall, as soon as practicable after the surrender of this Warrant, execute and deliver a new Warrant evidencing the rights of the Holder thereof to purchase the
balance of the Warrant Shares purchasable hereunder. 
 1.5 Exercise Upon the Occurrence of an Event Described in
Section 1.1. Notwithstanding anything herein to the contrary, contingent upon and effective immediately prior to any of the events set forth in clauses (i) and (ii) of Section 1.1, to the extent
not previously exercised, this 

  
 - 2 - 

 
Warrant shall automatically be exercised by the Holder pursuant to Section 1.3 herein without any further action necessary on the part of the Holder (a “Sale
Exercise”) unless the Holder notifies the Company in writing to the contrary prior to such automatic exercise; provided, however, that such automatic exercise shall not occur and this Warrant shall instead be terminated upon and
effective as of the occurrence of any of the events set forth in clauses (i) and (ii) of Section 1.1, if the Exercise Price equals or exceeds the Fair Market Value calculated in accordance with
Section 1.3(b) hereof in connection with such Sale Exercise. The Company shall provide notice to the Holder at least three business (3) days prior to the consummation of any of the events set forth in clauses
(i) and (ii) of Section 1.1. 
 2. Adjustment of Exercise Price and Number of Warrant Shares. The number and kind of
Warrant Shares purchasable upon the exercise of this Warrant and the Exercise Price shall be subject to adjustment from time to time upon the occurrence of the following events: 

2.1 Subdivision or Combination. If the Company at any time prior to the Expiration Date shall subdivide or combine its Common Stock,
the Exercise Price shall be proportionately decreased (and the number of Warrant Shares issuable upon exercise of this Warrant proportionately increased to the nearest whole) in the case of a subdivision or the Exercise Price shall be
proportionately increased (and the number of Warrant Shares issuable upon exercise of this Warrant proportionately decreased to the nearest whole) in the case of a combination. 

2.2 Reclassification, Reorganization and Consolidation. Subject to Section 1.5 above, in case of any
reclassification, capital reorganization or change in the type of securities of the Company issuable upon exercise of this Warrant (other than as a result of a subdivision, combination or stock dividend provided for in
Section 2.1 above or Section 2.3 below) or consolidation or merger involving the Company in which the Common Stock is converted into or exchanged for securities, cash or other property, then, as a
condition of such reclassification, reorganization, change, consolidation or merger, lawful provision shall be made, and duly executed documents evidencing the same from the Company or its successor shall be delivered to the Holder, so that the
Holder shall have the right at any time prior to the expiration of this Warrant to purchase, at a total price equal to that payable upon the exercise of this Warrant, the kind and amount of shares of stock and other securities or property receivable
in connection with such reclassification, reorganization, change, consolidation or merger by a holder of the same number and type of securities as were purchasable as Warrant Shares by the Holder immediately prior to such reclassification,
reorganization, change, consolidation or merger. In any such case appropriate provisions shall be made with respect to the rights and interest of the Holder so that the provisions hereof shall thereafter be applicable with respect to any shares of
stock or other securities or property deliverable upon exercise hereof, and appropriate adjustments shall be made to the Exercise Price per Warrant Share payable hereunder, provided the aggregate Exercise Price shall remain, as nearly as reasonably
may be, the same. 
 2.3 Stock Dividends. If the Company at any time prior to the Expiration Date shall pay a dividend with respect
to Common Stock payable in Common Stock (except any distribution accounted for in the foregoing Section 2.1), then the Exercise Price shall be adjusted (and the number of Warrant Shares issuable upon exercise of this
Warrant proportionately increased), from and after the record date for shareholders entitled to receive such dividend or distribution, to that price determined by multiplying the Exercise Price in effect immediately prior to such record date by a
fraction (a) the numerator of which shall be the total number of shares of Common Stock outstanding immediately prior to such dividend or distribution, and (b) the denominator of which shall be the total number of shares of Common Stock
outstanding immediately after such dividend or distribution. 
 2.4 Notice to Holder. The Company shall, promptly after making any
subdivision or combination provided for in Section 2.1 above, reclassification, capital reorganization or change in the 

  
 - 3 - 

 
type of securities of the Company issuable upon exercise of this Warrant provided for in Section 2.2 above or stock dividend provided for in
Section 2.3 above, give written notice (by first class mail, postage prepaid) to the Holder at the address of the Holder shown on the Company’s books. That notice shall set forth, in reasonable detail, the event
requiring the adjustment and the method by which the adjustment was calculated, and specify the Exercise Price then in effect after the adjustment and the increased or decreased number of Warrant Shares issuable upon exercise of this Warrant. 

3. Fractional Warrant Shares. No fractional Warrant Shares will be issued in connection with any exercise hereunder, but in lieu of such fractional
shares the Company shall make a cash payment therefor upon the basis of the Exercise Price then in effect. 
 4. Stock Fully Paid; Reservation of Warrant
Shares. All Warrant Shares issuable upon the exercise of the rights represented by this Warrant will, upon issuance, be fully paid and nonassessable. During the period within which the rights represented by this Warrant may be exercised, the
Company will at all times have authorized and reserved for the purpose of issuance upon exercise of the purchase rights evidenced by this Warrant, a sufficient number of shares of Common Stock to provide for the exercise of the rights represented by
this Warrant. In the event that there is an insufficient number of shares of Common Stock reserved for issuance pursuant to the exercise of this Warrant, the Company will take appropriate action to authorize an increase in the capital stock to allow
for such issuance or similar issuance acceptable to the Holder. 
 5. Securities Laws; Transfer. 

5.1 Compliance with Securities Act. The Holder, by acceptance hereof, agrees that this Warrant and the Warrant Shares are being
acquired for investment and that it will not offer, sell or otherwise dispose of this Warrant or any Warrant Shares except under circumstances which will not result in a violation of the Securities Act of 1933, as amended (the
“Act”). Upon exercise of this Warrant, the Holder hereof shall confirm in writing, in the form attached hereto as Attachment B, that the Warrant Shares so purchased are being acquired for investment and not with a view toward
distribution or resale. In addition, the Holder shall provide such additional information regarding such Holder’s financial and investment background as the Company may reasonably request. This Warrant and all Warrant Shares (unless registered
under the Act) shall be stamped or imprinted with a legend in substantially the following form: 
 THESE SECURITIES HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED
WITHOUT AN EFFECTIVE REGISTRATION STATEMENT OR QUALIFICATION RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION OR QUALIFICATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY
APPLICABLE STATE SECURITIES LAWS. 
 5.2 Transferability of Warrant. This Warrant may not be transferred or assigned in whole or in
part without compliance with applicable federal and state securities laws. 
 5.3 Disposition of Warrant Shares. The Holder
represents that, by accepting this Warrant, the Holder understands that this Warrant and any securities issuable upon exercise of this Warrant have not been registered for sale under Federal or state securities laws and are being offered and

  
 - 4 - 

 
sold to Holder pursuant to one or more exemptions from the registration requirements of such securities laws. The Holder understands that the Holder must bear the economic risk of the
Holder’s investment in this Warrant and any securities obtainable upon exercise of this Warrant for an indefinite period of time, as this Warrant and such securities have not been registered under Federal or state securities laws and therefore
cannot be sold unless subsequently registered under such laws, unless an exemption form such registration is available. The Holder is an “accredited investor” as defined in Rule 501(a) under the Act. 

Subject to the transfer restrictions referred to in the legend set forth in Section 5.1, this Warrant and all rights under this
Warrant are transferrable, in whole or in part, without charge to the Holder, upon the surrender of this Warrant with a properly executed assignment (in the form of Attachment C) delivered to the Company; provided, however, that no Holder of
this Warrant may sell, transfer, negotiate or assign all or any portion of this Warrant to any other person (other than its affiliates) without the prior written consent of the Company, which consent shall not be unreasonably withheld, conditioned
or delayed (provided, however, the Company shall have no obligation to give consent to any sale, transfer, negotiation or assignment of all or any portion of this Warrant unless and until (i) the transferee has agreed in writing for the benefit
of the Company to be bound by this Section 5 and (ii) the Holder shall have furnished to the Company an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration of
the Warrant Shares under the Act, provided that the Company will not require opinions of counsel for transactions made pursuant to Rule 144 of the Act except in unusual circumstances). This Warrant may not be transferred for less than [20,000
Warrant Shares (subject to appropriate adjustment in the event of any stock split, stock dividend or other similar event affecting the Common Stock); provided, however, in the event that this Warrant is transferred for less than all of the Warrant
Shares, then this Warrant and the new warrant issued by the Company pursuant to that transfer may not be transferred for less than all of the Warrant Shares after that transfer and the new warrants, including the Warrant, issued by the Company shall
reflect this restriction on transfer. 
 5.4 Register. The Company will maintain a register containing the name and address of the
Holder of this Warrant. The Holder may change its address as shown on the warrant register by written notice to the Company requesting such change. 

5.5 Market Standoff. Each Holder agrees, in connection with the Company’s initial public offering (the “IPO”) of
its equity securities, and upon request of the Company or the underwriters managing such offering, (a) not to sell, make any short sale of, loan, grant any option for the purchase of or otherwise dispose of any of the Warrants or the Warrant
Shares (other than those included in the registration, if any) without the prior written consent of the Company or such underwriters, as the case may be, for such period of time (not to exceed one hundred eighty (180) days (or such longer
period of time as may be required to accommodate regulatory restrictions on (i) the publication or other distribution of research reports and (ii) analyst recommendations and opinions, including, but not limited to, the restrictions
contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), as applicable, (or any successor rules or amendments thereto))) from the effective date of such registration as may be requested by the Company or such underwriters and (b) to execute
any agreement regarding (a) above as may be requested by the Company or underwriters at the time of the public offering; provided, that the officers and directors of the Company who own stock of the Company also agree to such restrictions. The
Company may impose stop transfer instructions to enforce this Section 5.5. 
 6. Rights of Stockholders. No Holder of this
Warrant shall be entitled to vote or receive dividends or be deemed the holder of capital stock or any other equity securities of the Company, nor shall anything 

  
 - 5 - 

 
contained herein be construed to confer upon the Holder of this Warrant, as such, any of the rights of a stockholder of the Company or any right to vote for the election of directors or upon any
matter submitted to stockholders at any meeting thereof, or to give or withhold consent to any corporate action (whether upon any recapitalization, issuance of stock, reclassification of stock, change of par value or change of stock to no par value,
consolidation, merger, conveyance, or otherwise) or to receive notice of meetings, or to receive dividends or subscription rights or otherwise until this Warrant has been exercised and Warrant Shares shall have become deliverable, as provided
herein. 
 7. Miscellaneous. 
 7.1
Governing Law. The terms and conditions of this Warrant shall be governed in all respects by the internal laws of the State of Delaware without regard to conflicts of laws principles that would result in the application of the laws of any
other jurisdiction. 
 7.2 Successors and Assigns. This Warrant shall be binding upon any successors or assigns of the Company and
inure to the benefit of the Holder and any successors or assigns. 
 7.3 Waivers and Amendments. This Warrant and any provisions
hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the Company and the Holder. 
 7.4
Loss of Warrant. Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of any such loss, theft or destruction, upon delivery of an indemnity agreement
reasonably satisfactory in form and amount to the Company, or, in the case of any such mutilation, upon surrender and cancellation of such Warrant, the Company will execute and deliver a new Warrant of like terms. 

7.5 Headings. The headings in this Warrant are for purposes of convenience and reference only, and shall not be deemed to constitute a
part hereof. 
 7.6 Notices. All notices and other communications given or made pursuant hereto shall be in writing and shall be
deemed effectively given: (a) upon personal delivery to the party to be notified; (b) when sent by confirmed facsimile if sent during normal business hours of the recipient, and if not so confirmed, then on the next business day;
(c) forty-eight (48) hours after having been sent by registered or certified mail, return receipt requested, postage prepaid, or after being deposited in the U.S. mail, postage prepaid; or (d) one (1) day after deposit with a
nationally recognized overnight courier, specifying next day delivery, with written verification of receipt, in the case of the Holder, addressed to the Holder at the address set forth on the signature page hereto, and, in the case of the Company,
to Alzheon, Inc., 111 Speen Street, Suite 306, Framingham, MA 01701, Attention: President, with a copy which shall not constitute notice to Latham & Watkins LLP, John Hancock Tower, 27th Floor, 200 Clarendon Street, Boston, MA 02116,
Attention: Peter N. Handrinos; or as subsequently modified by written notice to the other party. 
 7.7 Counterparts. This Warrant
may be executed in two or more counterparts (including, but not limited to, by facsimile, PDF or other electronic copy), each of which shall be deemed an original and all of which together shall constitute one instrument. 

(Signature page follows) 

  
 - 6 - 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by a duly authorized
officer. 
  

			
	ALZHEON, INC.

 
			
		
	By:	 	      

	
	Name: Martin Tolar, M.D., Ph.D.
	Title: President & Chief Executive Officer

 ACKNOWLEDGED: 

[ 🌑 ] 
  

			
	By:	 	      

	Name:
	Title:

 WARRANT SIGNATURE PAGE 

 ATTACHMENT A 

NOTICE OF EXERCISE 
 TO:
ALZHEON, INC. 
 ☐ The undersigned hereby elects to
purchase                    shares of Common Stock of Alzheon, Inc., a Delaware corporation (the “Company”), pursuant to the terms
of the attached Warrant, and tenders herewith payment of the purchase price of such shares in full. 
 ☐ The undersigned hereby elects
to convert the attached Warrant into Warrant Shares in the manner specified in Section 1.3 of the Warrant. This conversion is exercised with respect
to                        of the shares covered by the Warrant. 

[Check the box next to the paragraph above that applies.] 

1. Please issue a certificate or certificates representing said shares of Common Stock in the name of the undersigned or in such other name as
is specified below: 
  

					
	Name:	  	  
	  	
			
	Address:	  	  
	  	
			
		  	  
	  	

 2. The undersigned represents that the aforesaid shares of stock are being acquired for the account of the
undersigned for investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares. In support thereof, the undersigned has
executed an Investment Representation Statement attached hereto as Attachment B. 
 3. The undersigned, as a condition to the
Company’s issuance of the Warrant Shares, hereby joins in, becomes a party to and agrees to be bound by the terms and conditions of (i) the Stockholders Agreement, dated December 30, 2014, by and among the Company and the other
parties named therein (the “Stockholders Agreement”), as a “Key Holder” and “Stockholder” thereunder and (ii) the Right of First Refusal and Co-Sale Agreement, dated
December 30, 2014, by and among the Company and the other parties named therein (the “Co-Sale Agreement”), as a “Key Holder thereunder. The undersigned authorizes the signature page
hereto to be attached to the Stockholders Agreement and the Co-Sale Agreement as a counterpart signature page thereto. 

 

			
	HOLDER
	
	
     

 
			
		
	By:	 	      

			
		
	Title:	 	  

 
			
		
	Date:	 	  

 NOTICE OF EXERCISE 

 ATTACHMENT B 

INVESTMENT REPRESENTATION STATEMENT 

In connection with the exercise or conversion of a Warrant to purchase shares of Common Stock (the “Warrant Shares”) of
Alzheon, Inc., a Delaware corporation (the “Company”), the undersigned (the “Holder”) hereby represents and warrants to the Company the following: 

(a) Investment Experience. The Holder is an “accredited investor” within the meaning of Rule 501(a) of the Securities Act of
1933, as amended (the “Act”) , and has substantial experience in evaluating and investing in private placement transactions of securities in companies similar to the Company so that it is capable of evaluating the merits and risks
of its investment in the Company and has the capacity to protect its own interests. It is aware of the Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and
knowledgeable decision to acquire the Warrant Shares. 
 (b) Purchase Entirely for Own Account. The Warrant Shares are
being acquired for investment for the Holder’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof. Holder has no present intention of selling, granting any participation in, or
otherwise distributing the Warrant Shares. The Holder further represents that it does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations, to such person or to any third person, with
respect to the Warrant Shares. 
 (c) Restricted Securities. The Holder understands that the Warrant Shares are characterized as
“restricted securities” under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations such Warrant Shares may be
resold without registration under the Act only in certain limited circumstances. In this connection, the Holder represents that it is familiar with Rule 144, as presently in effect, and understands the resale limitations imposed thereby and by the
Act. The Holder must bear the economic risk of this investment indefinitely unless the Warrant Shares are registered pursuant to the Act, or an exemption from registration is available. The Holder understands that the Company has no present
intention of registering the Warrant Shares. The Holder also understands that there is no assurance that any exemption from registration under the Act will be available and that, even if available, such exemption may not allow the Holder to transfer
all or any portion of the Warrant Shares under the circumstances, in the amounts or at the times the Holder might propose. 
 (d) Bad
Actor Matters. None of the “Bad Actor” disqualifying events described in Rule 506(d)(1)(i) to (viii) promulgated under the Act (a “Disqualification Event”) is applicable to the Holder or any of its Rule 506(d)
Related Parties, except, if applicable, for a Disqualification Event as to which Rule 506(d)(2)(ii) or (iii) or (d)(3) is applicable. For purposes of this section, “Rule 506(d) Related Party” shall mean a person that is a
beneficial owner of the Holder’s securities for purposes of Rule 506(d) of the Act. 
  

			
	HOLDER

 
			
		
	By:	 	  

 
			
		
	Name:	 	  

 
			
		
	Title:	 	  

 
			
		
	Date:	 	  

 INVESTMENT REPRESENTATION STATEMENT 

 ATTACHMENT C 

FORM OF ASSIGNMENT 
 (To
assign the foregoing warrant, execute 
 this form and supply required information. 

Do not use this form to exercise the warrant.) 

FOR VALUE RECEIVED, the right
purchase                    Warrant Shares of Common Stock of Alzheon, Inc. and pursuant to the foregoing Warrant and all rights evidenced thereby
are hereby assigned to: 

                          
                                         
                                         
                    whose address is 

                          
                                         
                                         
                                         
               . 
  

                          
                                         
                                         
                                         
                
 Dated:
                    ,              

 

					
	Holder’s Signature:	  	  
	  	
			
	Holder’s Address:	  	  
	  	
			
		  	  
	  	

 Signature Guaranteed:
                                         
                    
 NOTE: The signature to this
assignment form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever. Officers of corporations and those acting in a fiduciary or other representative capacity should file
proper evidence of authority to assign the foregoing Warrant. 
 FORM OF ASSIGNMENT 

 ALZHEON, INC. 

SCHEDULE OF WARRANTS 
 TO PURCHASE
SHARES OF COMMON STOCK 
  

																	
	 Warrant Holder
	  	Date of
Issuance	 	  	Price	 	  	Expiration Date	 	  	Amount	 
	 Brookline Group LLC
	  	 	April 2, 2015	 	  	$	1.51	 	  	 	April 2, 2020	 	  	 	126,100	 
	 Scott A. Katzmann
	  	 	April 2, 2015	 	  	$	1.51	 	  	 	April 2, 2020	 	  	 	136,544	 
	 Harris R. Lyndon
	  	 	April 2, 2015	 	  	$	1.51	 	  	 	April 2, 2020	 	  	 	136,544	 
	 William B. Buchanan, Jr.
	  	 	April 2, 2015	 	  	$	1.51	 	  	 	April 2, 2020	 	  	 	23,864	 
	 Angela C. Dong
	  	 	April 2, 2015	 	  	$	1.51	 	  	 	April 2, 2020	 	  	 	12,721

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}]]